Novo Nordisk A/S (NOVO-B.CO)

DKK 771.6

(0.22%)

EBITDA Summary of Novo Nordisk A/S

  • Novo Nordisk A/S's latest annual EBITDA in 2023 was 113.33 Billion DKK , up 37.66% from previous year.
  • Novo Nordisk A/S's latest quarterly EBITDA in 2024 Q2 was 34.37 Billion DKK , up 1.16% from previous quarter.
  • Novo Nordisk A/S reported an annual EBITDA of 76.41 Billion DKK in 2022, up 21.44% from previous year.
  • Novo Nordisk A/S reported an annual EBITDA of 64.82 Billion DKK in 2021, up 12.19% from previous year.
  • Novo Nordisk A/S reported a quarterly EBITDA of 35.32 Billion DKK for 2024 Q1, up 15.41% from previous quarter.
  • Novo Nordisk A/S reported a quarterly EBITDA of 26.71 Billion DKK for 2023 Q2, down -3.14% from previous quarter.

Annual EBITDA Chart of Novo Nordisk A/S (2023 - 1989)

Historical Annual EBITDA of Novo Nordisk A/S (2023 - 1989)

Year EBITDA EBITDA Growth
2023 113.33 Billion DKK 37.66%
2022 76.41 Billion DKK 21.44%
2021 64.82 Billion DKK 12.19%
2020 58.56 Billion DKK 4.19%
2019 56.31 Billion DKK 12.95%
2018 51.56 Billion DKK -1.92%
2017 51.69 Billion DKK 1.06%
2016 50.57 Billion DKK -1.66%
2015 49.57 Billion DKK 37.79%
2014 38.09 Billion DKK 8.65%
2013 35.24 Billion DKK 8.57%
2012 30.44 Billion DKK 44.2%
2011 24.93 Billion DKK 3.01%
2010 21.25 Billion DKK 19.45%
2009 17.8 Billion DKK 25.69%
2008 14.48 Billion DKK 33.44%
2007 11.97 Billion DKK 0.87%
2006 10.75 Billion DKK 15.86%
2005 9.28 Billion DKK 9.59%
2004 8.47 Billion DKK 41.05%
2003 8.02 Billion DKK -0.73%
2002 6.05 Billion DKK 4.23%
2001 5.8 Billion DKK 18.27%
2000 4.9 Billion DKK 2.15%
1999 4.8 Billion DKK 129.68%
1998 2.09 Billion DKK -9.33%
1997 2.3 Billion DKK 7.15%
1996 2.15 Billion DKK -17.56%
1995 2.61 Billion DKK 7.9%
1994 2.42 Billion DKK 6.92%
1993 2.26 Billion DKK 178.73%
1992 812.28 Million DKK -47.35%
1991 1.54 Billion DKK 30.17%
1990 1.18 Billion DKK -6.33%
1989 1.26 Billion DKK 24.54%

Peer EBITDA Comparison of Novo Nordisk A/S

Name EBITDA EBITDA Difference
ALK-Abelló A/S 913 Million DKK -12313.034%
Bavarian Nordic A/S 2.05 Billion DKK -5423.516%
Genmab A/S 5.56 Billion DKK -1937.961%
Gubra A/S -28.89 Million DKK 392316.646%
Orphazyme A/S -26.04 Million DKK 435185.227%
Pharma Equity Group A/S -24.79 Million DKK 457098.266%
Zealand Pharma A/S -651.58 Million DKK 17493.259%